عربي
Vifor Pharma to spearhead development of vascular calcification field, through acquisition of Sanifit Therapeutics and... ST. GALLEN, Switzerland & PALMA, Spain & ZURICH -Monday 22 November 2021
(BUSINESS WIRE)-- Regulatory News: AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR Vifor Pharma has announced the acquisition of Sanifit Therapeutics, a Spanish clinical-stage cardio-renal biopharmaceutical company focused on treatments for end-stage kidney disease patients with progressive...
VFMCRP receives positive CHMP opinion for Tavneos® for the treatment of ANCA-associated vasculitis
-Friday 12 November 2021 
Committee for Medicinal Products for Human Use (CHMP) recommends approval of first orally administered therapy for the treatment of ANCA-associated vasculitis (GPA and MPA) in Europe European Commission decision for EU Marketing Authorization expected in Q1 2022 (BUSINESS WIRE)--...
Vifor Pharma and Angion report topline results from phase-III registration trial of ANG-3777 in kidney transplant...
-Wednesday 27 October 2021
(BUSINESS WIRE) -- Regulatory News: AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR Vifor Pharma and Angion Biomedica Corp. (NASDAQ: ANGN) today announced that the phase-III trial of Angion’s ANG-3777 did not demonstrate a statistically significant difference from placebo on the primary...
Vifor Pharma announces changes to its Executive Committee -Tuesday 12 October 2021
Executive committee members Lee Heeson and Gregory Oakes to leave the company for personal reasons Succession planning ongoing (BUSINESS WIRE)-- Regulatory News: AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR Vifor Pharma Group today announced changes to its Executive Committee as...
VFMCRP announces approval for TAVNEOS® (avacopan) for the treatment of ANCA-associated vasculitis in Japan
-Tuesday 28 September 2021
(BUSINESS WIRE) -- Vifor Fresenius Medical Care Renal Pharma (VFMCRP) today announced that Japan’s Ministry of Health and Labor Welfare (MHLW) has granted its partner, Kissei Pharmaceutical Co., Ltd., marketing authorization approval for TAVNEOS® for the treatment of patients with...
Vifor Pharma and Travere Therapeutics announce licensing agreement for the commercialization of sparsentan in Europe,...
-Thursday 16 September 2021
Sparsentan is a potential first-in-class treatment to address significant unmet medical need in rare kidney disorders focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN) Vifor Pharma obtains exclusive commercialization rights for sparsentan in Europe, Australia and New...
Vifor Pharma’s Ferinject® granted new recommendations in updated 2021 ESC heart failure... -Tuesday 31 August 2021
2021 European Society of Cardiology (ESC) guidelines for acute and chronic heart failure (HF) includes new recommendations on management of iron deficiency with Ferinject® (ferric carboxymaltose) in patients with HF Periodic screening for iron deficiency and the use of Ferinject® to...
Vifor Pharma and Cara Therapeutics announce U.S. FDA approval of KORSUVA™ injection for the treatment of...
-Tuesday 24 August 2021
First and only therapy approved by the FDA for the treatment of pruritus associated with chronic kidney disease (CKD-aP) in adults undergoing hemodialysis Promotional launch of KORSUVA™ injection in the U.S. is expected in Q1 2022, with reimbursement in H1...
Vifor Pharma reports strong H1 2021 growth, on track to meet full year guidance1 -Thursday 5 August 2021
Net sales up 5.0% and EBITDA up 5.3% at constant exchange rates (CER), as patient access recovered in line with easing COVID-19 restrictions in key markets Ferinject® / Injectafer® sales up 22.8% at CER ‒ strong recovery in Q2 in line with lockdown easing and better patient access to...
Abbas Hussain Appointed as New Chief Executive Officer of Vifor Pharma -Friday 25 June 2021
Abbas Hussain will take over as CEO of the Vifor Pharma Group on 16 August 2021 Succeeding Stefan Schulze, who has decided to step down and leave the company for personal reasons (BUSINESS WIRE)-- Regulatory News: Abbas Hussain (56, British citizen) has a successful and...
Vifor Pharma to revise DIAMOND study, readout expected in H2 2021 -Thursday 24 June 2021
- Vifor Pharma will host a conference call today at 10:30 am CET - (BUSINESS WIRE) -- Regulatory News: Vifor Pharma Group today announced that the phase-IIIb DIAMOND study has been amended with new and clinically relevant endpoints, including a new primary endpoint of efficacy in...
93rd Vifor Pharma Group Annual General Meeting -Thursday 6 May 2021
(BUSINESS WIRE) -- Regulatory News: At today’s 93rd Annual General Meeting of Vifor Pharma Ltd., shareholders approved all proposed resolutions put forward by the Board of Directors. In view of the ongoing COVID-19 pandemic and in accordance with Ordinance 3 on measures to combat the...
VFMCRP announces positive results of phase-III clinical trial of Velphoro® in China
-Friday 30 April 2021
(BUSINESS WIRE) -- Regulatory News: Vifor Fresenius Medical Care Renal Pharma (VFMCRP) today announced positive results from a phase-III study in China (PA-CL-CHINA-01), evaluating the efficacy of Velphoro® (PA21) compared to sevelamer carbonate in lowering and maintaining serum phosphorus...
Vifor Pharma and Angion announce completion of enrollment in phase-II study of ANG-3777 for cardiac-surgery associated...
-Thursday 29 April 2021
(BUSINESS WIRE)-- Regulatory News: This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210428005922/en/ Vifor Pharma and Angion Biomedica Corp. (NASDAQ: ANGN), today announced completion of enrollment for Angion’s AKI-002-15 study,...
First patient enrolled in CARE-HK in HF to evaluate role of Veltassa® (patiromer) in enabling RAASi... -Wednesday 28 April 2021
CARE-HK in heart failure (HF) is the first global registry of around 5,000 patients with chronic HF who have or are at high risk for hyperkalemia (HK), in Europe and the US CARE-HK in HF is designed to evaluate the use of Veltassa® in enabling patients to remain on RAASi therapy in HF...
VFMCRP and Cara Therapeutics announce European Medicines Agency has accepted to review the Marketing Authorization...
-Tuesday 30 March 2021
(BUSINESS WIRE) -- Regulatory News: Vifor Fresenius Medical Care Renal Pharma (VFMCRP) and Cara Therapeutics, Inc. (Nasdaq: CARA) today announced that the European Medicines Agency (EMA) accepted to review the Marketing Authorization Application (MAA) for difelikefalin injection for the...
Vifor Pharma to propose Åsa Riisberg for appointment to Board of Directors -Friday 26 March 2021
(BUSINESS WIRE)-- Regulatory News: Vifor Pharma is pleased to announce that the Board of Directors will propose Åsa Riisberg for election to the Board at the Annual General Meeting on 6 May 2021. Åsa Riisberg, a Swedish citizen, was formerly Partner and member of the extended Executive...
Vifor Pharma and Cara Therapeutics announce U.S. FDA acceptance and Priority Review of NDA for KORSUVA™* injection...
-Monday 8 March 2021
FDA has set Prescription Drug User Fee Act (PDUFA) target action date of 23 August 2021 If approved, KORSUVA™ injection would be first therapy for treatment of pruritus in hemodialysis patients (BUSINESS WIRE)-- Regulatory News: This press release features multimedia. View the...
Vifor Pharma delivers strong full year results 2020 with an EBITDA of 576 million Swiss Francs representing over 29%... -Wednesday 3 March 2021
Net sales up 3.7% at constant exchange rates (CER), despite significant impact of COVID-19 Continued strong increase in EBITDA by 29.4% at CER, owing to a mix of one-time and sustainable cost measures Ferinject® / Injectafer® sales showed rapid improvements in early H2 2020 following...
Vifor Pharma to propose Dr Alexandre LeBeaut as Board member -Tuesday 2 February 2021
Dr Alexandre LeBeaut to be proposed to Annual General Meeting for appointment to Board Dr Gianni Zampieri and Gilbert Achermann will not stand for re-election (BUSINESS WIRE)-- Regulatory News: Vifor Pharma today announced that the Board of Directors will propose Dr Alexandre...
Permalink :- http://aetoswire.com/newsroom/1/vifor-pharma